Jonathan Zwart, MD
Otolaryngology · Vancouver, WANPI 1992851455
Payments from drug & device makers
What this record shows
Intersect ENT, Inc. accounts for 66.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,472 and has fallen 90.5% since, to $235 in 2025.
Across 19 payments — averaging $158.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$2K
- Stryker$288
- Optinose US, Inc.$216
- Medtronic$198
- GSK$122
- Acclarent, Inc$120
- plus $52 from 2 others
What the payments were for
- Travel & lodging$1,54751%
- Food & beverage$1,46049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 8 | $2,012 |
| Stryker | 3 | $288 |
| Optinose US, Inc. | 2 | $216 |
| Medtronic(2 entities) | 2 | $198 |
| GSK | 1 | $122 |
| Acclarent, Inc | 1 | $120 |
| Sanofi | 1 | $30 |
| Pulmonx Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPEL$2,037
- SINUVA$1,924
- ENTELLUS - XPRESS ENT DILATION SYSTEM$252
- Xhance$216
- NUCALA$122
- TruDi Nav Cable$120
How this compares
$3,008 in reported general payments places this provider in the 85th percentile of 254 otolaryngology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 267 | $6,706 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 15 | $2,593 |
| Azelastine Hcl | 21 | $493 |
| Mometasone Furoate | 20 | $419 |
| Cyproheptadine Hcl | 22 | $234 |
| Triamcinolone Acetonide | 11 | $128 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $118 |
| Amitriptyline Hcl | 22 | $110 |
| Hydrochlorothiazide | 12 | $20 |
| Prednisone | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Vancouver
- Todd BerinsteinVancouver$14K
- David BloomVancouver$2K
- Greg DavisPuyallup$531K
- Ian HumphreysSeattle$43K
- Douglas BackousPuyallup$36K
- Craig MillerSeattle$24K
- Sachin GuptaSeattle$23K
- Sharon CushingSeattle$19K
- Ronald KruegerMukilteo$19K
- Eric WatermanBellevue$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.